TRPM4

Across TCGA pan-cancer cohorts, TRPM4 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TRPM4 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher TRPM4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRPM4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, THYM, and UCEC are the cancer types where TRPM4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.145	0.888	<.001	45	view →
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
UCEC	OS	Median	All	0.973	0.639	.008	36	view →
THCA	DFS	Median	II,III,IV	0.071	0.762	<.001	18	view →
PRAD	DFS	Median	All	0.617	0.886	.038	6	view →
BLCA	DFS	Median	III,IV	0.121	0.488	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TRPM4–ACC (OS)

Open the ACC breakdown →